Loading
Life sciences · Safety recall
U.S. Food and Drug Administration · September 9, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Safety recall.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
FDA enforcement report D-0815-2026. This is a regulatory safety action, not a clinical study. Classification: Class II. Status: Ongoing. Recalling firm: Baxter Healthcare Corporation. Initiated as: Voluntary: Firm initiated. Product: Clindamycin Injection USP in 5% Dextrose, 900 mg per 50 mL (12 mg/mL) in GALAXY 50 mL Single Dose Container, Rx only, Sterile Nonpyrogenic, Baxter Healthcare Corporation, Deerfield, IL 60015 USA, NDC 0338-3814-50. Reason for recall: CGMP Deviations Distribution: US Nationwide; Puerto Rico; and Chile.